米国市場銘柄情報

BTAI バイオエクセル・セラピューティクス

銘柄追加

2.560
+0.020+0.79%

終値 05/02 16:00 ET

2.600
+0.040+1.56%

市場後 18:58 ET

9,480.84万時価総額-416直近PER

バイオエクセル・セラピューティクスに関するコメント

ログインコメントを投稿

Jaguar8

04/24 22:31

$バイオエクセル・セラピューティクス(BTAI.US)$
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...

Trytosaveabit

04/10 19:08

Hmm?

$バイオエクセル・セラピューティクス(BTAI.US)$ BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia

Trytosaveabit

03/15 19:13

$バイオエクセル・セラピューティクス(BTAI.US)$ BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE